<DOC>
	<DOCNO>NCT00400816</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well temozolomide work treat patient newly diagnose anaplastic oligodendroglioma mixed oligoastrocytoma .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma Mixed Oligoastrocytoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine progression-free survival patient newly diagnose anaplastic oligodendroglioma ( AO ) mix oligoastrocytoma ( MOA ) treat temozolomide . - Determine response rate patient . - Assess quality life patient AO MOA treat regimen . OUTLINE : This parallel-group , multicenter study . Patients stratify accord disease type ( anaplastic oligodendroglioma v mixed oligoastrocytoma ) . Patients receive oral temozolomide daily day 1-7 15-21 . Treatment repeat every 28 day 8 course absence disease progression unacceptable toxicity . Quality life assess baseline , course 1 , 3 , 5 , 7 , every 3 month first year completion treatment , every 4 month second year , every 6 month third fourth year , year thereafter . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm anaplastic oligodendroglioma mixed oligoastrocytoma meet 1 follow criterion : Bidimensionally measurable disease Evaluable disease Nonevaluable disease demonstrate gross total surgical resection No immediate need cranial irradiation PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Life expectancy ≥ 12 week Absolute granulocyte count ≥ 1,500/mm³ Hemoglobin ≥ 10.0 g/dL Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 2.0 time ULN AST ≤ 3.0 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No infection require systemic antibiotic within past 14 day No malignancy within past 5 year except carcinoma situ cervix nonmelanoma skin cancer No unrelated medical problem would preclude study compliance PRIOR CONCURRENT THERAPY : No prior chemotherapy malignancy No prior radiotherapy brain No surgery require general anesthesia &gt; 2 hour duration within past 10 day No prior temozolomide Concurrent steroid allow provide dose stable decrease least 1 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>